Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sarmad Sadeghi, MD
University of Southern California
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Lac+usc Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Usc Norris Oncology/hematology - Newport Beach
Newport Beach, California, United States
- Uc Davis Comprehensive Cancer Center
Sacramento, California, United States
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- Levine Cancer Institute-Carolinas Medical Center
Charlotte, North Carolina, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Nov 2016
- Primary completion
- 31 Dec 2027
- Completion
- 31 Dec 2030
- Last update posted
- 9 Jun 2026
- Registered enrollment
- 70
- Registry id
- NCT02717156
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.